Drug Profile


Alternative Names: Lonsurf; S 95005/TAS-102; T15, T20; T15/T20; TAS-102; Trifluridine/tipiracil; Trifluridine/tipiracil hydrochloride

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer 3SBio; Boehringer Ingelheim; Servier; Taiho Pharmaceutical
  • Class Antineoplastics; Nucleosides; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Thymidine phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer
  • Phase III Gastric cancer
  • Phase II Oesophageal cancer; Small cell lung cancer
  • Phase I Gastrointestinal cancer; Solid tumours

Most Recent Events

  • 17 Aug 2017 Laboratorios Servier initiates enrolment in an early access phase IIIb trial for Colorectal cancer (Refractory metastatic disease) in Belgium (PO, Tablet) (EudraCT2016-002311-18) after September 2016
  • 16 Aug 2017 Servier and Amgen Australia plans a phase Ib/II PIT trial for Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Australia in September 2017 (ACTRN12617001190392)
  • 23 Jun 2017 Taiho Pharmaceutical plans the TRUSTY phase II/III trial for Colorectal cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in Japan (JapicCTI-173618)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top